Healthcare / Medical DistributionNYSE
$266.28
+0.00 (+0.00%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 23% · confianza 25%
FCF escenarios
weak_data · normalized FCF $3.2B · quality 55.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
24/100
D
Piotroski
6/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$51.8B
P/E
N/A
•EV/EBITDA
N/A
•ROE
103.1%
↑Gross Margin
3.6%
↓Debt/Equity
5.00
↑Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2007–2025 · 18 años de histórico normalizado
Revenue CAGR
+9.2%
FCF CAGR
+6.1%
FCF margin
1.0%
FCF / Net income
2.06x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $321.33B · net income $1.55B · FCF $3.21B
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||||||||||||
| Revenue | $321.33B | $321.33B | $293.96B | $262.17B | $238.59B | $213.99B | $189.89B | $179.59B | $167.94B | $153.14B | $146.85B | $135.96B | $119.57B | $87.96B | $78.08B | $78.70B | $77.78B | $71.76B | $70.19B | $65.67B |
| Net Income | $1.55B | $1.55B | $1.51B | $1.75B | $1.70B | $1.54B | $-3.41B | $855.4M | $1.66B | $364.5M | $1.43B | $-138.2M | $274.2M | $433.7M | $719.0M | $706.6M | $636.7M | $503.4M | $250.6M | $469.2M |
| EBITDA | $3.68B | $3.68B | $3.27B | $3.30B | $3.06B | $2.86B | $-4.74B | $1.57B | $1.91B | $1.46B | $1.89B | $670.9M | $970.8M | $1.06B | $1.44B | $1.29B | $1.18B | — | — | — |
| EPS | 7.96 | 7.96 | 7.53 | 8.53 | 8.04 | 7.39 | -16.65 | 4.04 | 7.53 | 1.64 | 6.32 | -0.63 | 1.16 | 1.84 | 2.80 | 2.54 | 2.22 | 1.66 | 0.77 | 1.25 |
| Gross Margin | 3.6% | 3.6% | 3.4% | 3.4% | 3.5% | 3.2% | 2.7% | 2.9% | 2.7% | 3.0% | 2.9% | 2.6% | 2.5% | 2.9% | 3.4% | 3.1% | 3.0% | 2.9% | 2.9% | 3.4% |
| Operating Margin | 0.8% | 0.8% | 0.7% | 0.9% | 1.0% | 1.1% | -2.7% | 0.6% | 0.9% | 0.7% | 1.0% | 0.3% | 0.7% | 1.0% | 1.7% | 1.5% | 1.4% | 1.2% | 1.2% | 1.2% |
| Net Margin | 0.5% | 0.5% | 0.5% | 0.7% | 0.7% | 0.7% | -1.8% | 0.5% | 1.0% | 0.2% | 1.0% | -0.1% | 0.2% | 0.5% | 0.9% | 0.9% | 0.8% | 0.7% | 0.4% | 0.7% |
| Balance Sheet | ||||||||||||||||||||
| Debt/Equity | 5.00 | 5.00 | 5.90 | 7.94 | -21.90 | 28.58 | -3.55 | 1.40 | 1.42 | 1.66 | 1.68 | 5.67 | 1.03 | 0.61 | 0.57 | 0.34 | 0.45 | 0.43 | 0.44 | — |
| Cash Flow | ||||||||||||||||||||
| Free Cash Flow | $3.21B | $3.21B | $3.00B | $3.45B | $2.21B | $2.23B | $1.84B | $2.03B | $1.07B | $1.04B | $2.71B | $3.69B | $1.20B | $585.7M | $1.17B | $1.01B | $932.2M | $637.9M | $599.8M | $1.10B |
| Returns | ||||||||||||||||||||
| ROE | 103.1% | 103.1% | 233.6% | 334.3% | -803.0% | 689.5% | 334.5% | 29.7% | 56.5% | 17.7% | 67.1% | -22.4% | 14.1% | 18.8% | 29.3% | 24.6% | 21.6% | 18.5% | 9.2% | 15.1% |
| Growth & Yield | ||||||||||||||||||||
| Revenue Growth | 9.3% | 9.3% | 12.1% | 9.9% | 11.5% | 12.7% | 5.7% | 6.9% | 9.7% | 4.3% | 8.0% | 13.7% | 35.9% | 12.7% | -0.8% | 1.2% | 8.4% | 2.2% | 6.9% | — |
| EPS Growth | 5.7% | 5.7% | -11.7% | 6.1% | 8.8% | 144.4% | -512.1% | -46.3% | 359.1% | -74.1% | 1103.2% | -154.3% | -37.0% | -34.3% | 10.2% | 14.4% | 33.7% | 115.6% | -38.4% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
43.7%
EPS terminal req.
$23.63
Spread vs growth
-38.0%
5Y implied EPS CAGR
29.1%
EPS terminal req.
$28.59
Spread vs growth
-23.4%
10Y implied EPS CAGR
19.2%
EPS terminal req.
$46.04
Spread vs growth
-13.5%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Unavailable: positive start/end prices are required.